The Algerian Press Service has announced a collaboration between public startup accelerator Algeria Venture and Roche, a Swiss company specialising in diagnosis and biotechnology, to help boost Algerian startups in health and medical technology.
The two parties signed a memorandum of agreement to offer support for startups by providing them with specialised resources, expertise, and networking opportunities, to help accelerate the adoption of innovative solutions for health and care in the country.
In a LinkedIn post, Algeria Venture welcomed the partnership as helping to bring “next-level innovation, cutting-edge solutions, and a total disruption of the status quo”.
Country manager for Roche Algeria, Khalil Kadaoui, also took to LinkedIn to share his thoughts on the partnership, commenting: “We will be working together pledging our resources, expertise, creativity, networks and passion to support startups addressing patient journeys and healthcare ecosystems challenges. This will contribute to economic diversification and improved patient care in Algeria.”
Algeria Venture is a state-owned startup accelerator, described as “offering and facilitating logistical and development structures for startups and incubator as well as various accompaniment programs complying with international standards”.
In another recent announcement, the accelerator announced the launch of its collaboration with Google for Startups, with a total of twelve startups selected to join the program, where they will be able to access advice from experts, pitch their ideas, and share their experiences with other innovators.
Also on innovation, for our first international webinar last week we were joined by a panel of health tech experts to discuss current international digital health development, covering digital capabilities, projects, and priorities from country contexts including Spain, Bermuda, and the UK.
Elsewhere, Florida-based surgical robotics company Medical Microinstruments, Inc. (MMI) has raised $110 million in Series C funding for microsurgery innovation, which is to be used to support the commercialisation of the company’s Symani® Surgical System and to accelerate “advanced technology capabilities” across the globe.
